Anti-aging drugs die young.

Unity, a high-profile biotech company, has received $200 million in investments from prominent investors including Bezos and Arch.
today's failure has made him feel like a pre-clinical company back to pre-liberation.
many dangerous lifestyles, such as smoking and alcoholism, increase the risk of disease, but the most dangerous way of life is to stay alive.
age is the biggest risk factor for many diseases, so if it slows down aging, the risk of many chronic diseases and tumors will decrease.
, of course, slowing down aging is a counter-rule of nature and may not be good for the survival of species, jobs did not say that death is the best gift to life.
it is not easy to combat evolutionary stress in any way, and it is more difficult to use drugs.
Unity is not trying to reduce the age of OA patients by 20 years to alleviate symptoms, a goal that currently has no technology to do.
aging is a whole phenomenon, but in every tissue, each organ also has a unique local characteristics.
Unity targets specific accompanying changes in the locality of aging in the joints, specifically the selective removal of senescing cells.
hypothesis is that some senescing cells, while still functioning normally, are no longer divided and still at rest.
these cells secrete a variety of aging-related growth factors (SASPs) that alter the microenn environment of tissues, causing inflammation, tissue damage, etc., and may be associated with common chronic diseases such as arteriosclerosis, arthritis, cognitive impairment, etc.
increases with age, previous studies have shown that removing senescies with genetic techniques can extend the lifespan of mice by 25 percent.
the BCL inhibitor navitoclax, which induces apoptosis, removed senescing cells in mice and almost copied the ideosis of genes.
UBX0101 is a p53/MDM2 blocker that induces aging apoptosis.
so there is no essential difference between this agent and kinase inhibitors, hanging anti-aging signs is somewhat of a suspicion of hanging sheep's heads selling dog meat stalls.
esolysed early drug development is bound to be an incurable indicator, as symptom improvement is the main optimization indicator.
with the increase in understanding of biological processes and the emergence of modern, new drug research and development techniques based on their machinery, there have been more drugs to change the progression of disease.
but which machine is not as good as the strategy of returning to old age can better cure all kinds of common public diseases, so this direction is the direction of the sea.
companies are now tracking this ambitious goal, most notable for its wealthy Calico.
The Google-funded biotech company is run by Art Levinson, the former president of Genentech, and now GSK's research and development boss Hal Barron and Insitro founder Daphne Koller have both worked for the company this year.
are Life Bio, Juvenescene and so on.
is now the most leading product or metformin, mTOR inhibitors and other old drugs, adaptive disorders are basically common popular diseases.
Bio's CEO says the long-term goal is to extend life to 150 years through gene therapy.
pain relief is a difficult market, OA in the pain relief market is still a difficult point.
only NGF antibodies have recently shown sufficient efficacy and treatment windows, although the window is very narrow and is estimated to tolerate only one dose.
also Centerxion has a capsaicin preparation in Phase III Clinical.
controlling disease at the tissue level (i.e., removing certain types of cells to improve the micro-environment) is highly difficult to treat any disease, and may be more difficult for OA.
.